These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 28707379)

  • 1. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
    Puri R; Otaegui I; Sabaté M; Serra-Peñaranda A; Puigfel M; Perez de Prado A; Nombela-Franco L; de la Torre Hernandez JM; Ortas Nadal R; Iniguez-Romo A; Jiménez G; Fernandez-Vazquez F; Cuellas-Ramon C; Gonzalo N; Alfonso Jiménez Diaz V; Duocastella L; Molina M; Amoros M; Perez I; Barria Perez A; Pelletier Beaumont E; Nicholls SJ; Garcia Del Blanco B; Rodés-Cabau J
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):435-443. PubMed ID: 28707379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
    Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer-coated sirolimus-eluting stents.
    Legutko J; Gil RJ; Buszman PE; Kaluza GL; Mintz GS; Roleder T; Krol M; Wojdyla R; Pawlowski T; Brzezinski M; Kondys M; Skwarna B; Jakala J; Zasada W; Partyka L; Dudek D
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):302-309. PubMed ID: 29027737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial.
    Li B; Jin QH; Chen YD; Wang CQ; Shi B; Su X; Fu GS; Wu YQ; Zhou XC; Yuan ZY
    Trials; 2019 Jun; 20(1):335. PubMed ID: 31174600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study.
    Worthley SG; Abizaid A; Kirtane AJ; Simon DI; Windecker S; Brar S; Meredith IT; Shetty S; Sinhal A; Almonacid AP; Chamié D; Maehara A; Stone GW;
    JACC Cardiovasc Interv; 2017 Jan; 10(2):147-156. PubMed ID: 28104208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study.
    Lee SW; Lam SC; Tam FC; Chan KK; Shea CP; Kong SL; Wong AY; Yung A; Zhang LW; Tse HF; Wu KK; Chan R; Haude M; Mehran R; Mintz GS; Maehara A
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
    Yu M; Xu B; Kandzari DE; Wu Y; Yan H; Chen J; Qian J; Qiao S; Yang Y; Gao RL
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):405-11. PubMed ID: 23857821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography findings after chronic total occlusion interventions: Insights from the "AngiographiC evaluation of the everolimus-eluting stent in chronic Total occlusions" (ACE-CTO) study (NCT01012869).
    Sherbet DP; Christopoulos G; Karatasakis A; Danek BA; Kotsia A; Navara R; Michael TT; Roesle M; Rangan BV; Haagen D; Garcia S; Maniu C; Pershad A; Abdullah SM; Hastings JL; Kumbhani DJ; Luna M; Addo T; Banerjee S; Brilakis ES
    Cardiovasc Revasc Med; 2016; 17(7):444-449. PubMed ID: 27133499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).
    Chevalier B; Smits PC; Carrié D; Mehilli J; Van Boven AJ; Regar E; Sawaya FJ; Chamié D; Kraaijeveld AO; Hovasse T; Vlachojannis GJ
    Circ Cardiovasc Interv; 2017 Dec; 10(12):. PubMed ID: 29246909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.
    Hashikata T; Tojo T; Namba S; Kitasato L; Hashimoto T; Kameda R; Shimohama T; Yamaoka-Tojo M; Ako J
    Heart Vessels; 2016 Feb; 31(2):206-11. PubMed ID: 25362579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography.
    Staico R; Costa MA; Chamié D; Bezerra H; Armaganijan LV; Costa RA; Costa JR; Siqueira D; Centemero M; Chaves Á; Tanajura LF; Abizaid A; Feres F; Sousa JE; Sousa AG
    Int J Cardiovasc Imaging; 2013 Jun; 29(5):977-88. PubMed ID: 23456358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
    Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vulnerable struts with CRE8, Biomatrix and Xience stents assessed with OCT and their correlation with clinical variables at 6-month follow-up: the CREBX-OCT study.
    Giglioli C; Formentini C; Romano SM; Cecchi E; Baldereschi GJ; Landi D; Chiostri M; Prati F; Marchionni N
    Int J Cardiovasc Imaging; 2020 Feb; 36(2):217-230. PubMed ID: 31667661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.
    Gil RJ; Bil J; Legutko J; Pawłowski T; Gil KE; Dudek D; Costa RA
    Int J Cardiovasc Imaging; 2018 Mar; 34(3):353-365. PubMed ID: 28965166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very early neointimal coverage of new biodegradable polymer drug-eluting stent compared with durable polymer everolimus-eluting stent evaluated by optical frequency domain imaging.
    Kobayashi N; Ito Y; Yamawaki M; Araki M; Sakai T; Sakamoto Y; Mori S; Tsutsumi M; Nauchi M; Honda Y; Tokuda T; Makino K; Shirai S; Hirano K
    Int J Cardiovasc Imaging; 2018 Apr; 34(4):515-522. PubMed ID: 29159531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.